Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer

14 Feb 2024

Abstract excerpt

Immune checkpoint inhibitors (ICI) improve overall survival in patients with metastatic urothelial cancer (mUC), but therapeutic success at the individual patient level varies significantly. Here we identify predictive markers of response, based on whole-genome DNA (n = 70) and RNA-sequencing (n = 41) of fresh metastatic biopsy samples, collected prior to treatment with pembrolizumab. We find that PD-L1 combined...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to Cancer Immunotherapy and Biomarkers
Share to Urinary and Genital Oncology Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38355607
DOI: 10.1038/s41467-024-45714-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerPMID 38355607Read ↗

T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancerSemantic proximity Read ↗

Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity Read ↗

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity Read ↗

The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohortSemantic proximity Read ↗

EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer.Semantic proximity Read ↗

Single-cell trajectories in metastatic urothelial carcinoma reveal tumor–immune reprogramming and macrophage-driven resistance to PD-(L)1 blockadeSemantic proximity Read ↗

A transcriptome-wide meta-analysis reveals lack of cancer-cell intrinsic determinants of response to immune checkpoint blockadeSemantic proximity Read ↗

Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohortsSemantic proximity Read ↗

Tumor Niche Network-Defined Subtypes Predict Immunotherapy Response of Esophageal Squamous Cell CancerSemantic proximity Read ↗

Contribution of systemic and somatic factors to clinical response and resistance in urothelial cancer: an exploratory multi-omic analysisSemantic proximity Read ↗

Single-cell RNA sequencing reveals the cellular and molecular characteristics of high-grade and metastatic bladder cancerSemantic proximity Read ↗

Multimodal integration of blood RNA and ctDNA reflects response to immunotherapy in metastatic urothelial cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.